Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.62 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | QDPR | P09417 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 3/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD5 | P21918 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1764922 | 0.98 | HTR2C (0.64) | HTR2CSLC18A3SIGMAR1QDPRKDM1A | |
| SCHEMBL25381551 | 0.89 | DRD2 (0.51) | HTR2CSLC18A3SIGMAR1KDM1ADRD2 | |
| SCHEMBL20882077 | 0.89 | DRD2 (0.51) | HTR2CSLC18A3SIGMAR1KDM1ADRD2 | |
| SCHEMBL31252221 | 0.89 | DRD2 (0.51) | HTR2CSLC18A3SIGMAR1KDM1ADRD2 | |
| Hydrochloric Acid SCHEMBL30149814 | 0.87 | HTR2C (0.51) | HTR2CSLC18A3SIGMAR1KDM1ADRD2 | |
| SCHEMBL957833 | 0.86 | KDM1A (0.55) | HTR2CKDM1ADRD2DRD1DRD4 | |
| SCHEMBL29427010 | 0.86 | KDM1A (0.55) | HTR2CKDM1ADRD2DRD1DRD4 | |
| Iodide SCHEMBL5548757 | 0.84 | KDM1A (0.53) | HTR2CKDM1ADRD2DRD1DRD4 | |
| Tert-Butyl Formate SCHEMBL28046430 | 0.83 | HTR2C (0.49) | HTR2CSLC18A3SIGMAR1QDPRKDM1A | |
| SCHEMBL3976082 | 0.82 | DRD2 (0.55) | HTR2CKDM1ADRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731223-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | Universitat De Barcelona (ES) | 2026-04-29 | — | — | EP | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2024261340-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | UNIVERSITAT DE BARCELONA (ES) | 2024-12-26 | — | — | WO | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20070032501-A1 | Aryl pyridines and methods of their use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2007-02-08 | — | — | US | disclosed |
| WO-2007016674-A2 | 2-AMINOARYL PYRIDINES AS PROTEIN KINASES INHIBITORS | LEXICON GENETICS INCORPORATED (US) | 2007-02-08 | — | — | WO | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| US-3995045-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885SLC18A3 162/4885SIGMAR1 50/4885 |
| US-20070032501-A1 | Aryl pyridines and methods of their use | PNPO, PAH, AHR | HTR2C 817/4885SLC18A3 2226/4885SIGMAR1 2588/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | HTR2C 4530/4885SLC18A3 4364/4885SIGMAR1 4076/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | HTR2C 1015/4885SLC18A3 1655/4885SIGMAR1 98/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | HTR2C 1015/4885SLC18A3 1655/4885SIGMAR1 98/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885SLC18A3 162/4885SIGMAR1 50/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | HTR2C 1015/4885SLC18A3 1655/4885SIGMAR1 98/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | HTR2C 1015/4885SLC18A3 1655/4885SIGMAR1 98/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | HTR2C 252/4885SLC18A3 1966/4885SIGMAR1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.